Cerenis hires John Paolini as CMO
This article was originally published in Scrip
Dr John Paolini has joined Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies to treat cardiovascular and metabolic diseases, as chief medical officer. Dr Paolini has over 15 years of clinical and research experience in cardiovascular disease, having led development programmes for various drugs at both Merck & Co and Bayer Healthcare Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.